OBJECTIVE: Wound monocyte-derived macrophage plasticity controls the initiation and resolution of inflammation that is critical for proper healing, however, in diabetes mellitus, the resolution of inflammation fails to occur. In diabetic wounds, the kinetics of blood monocyte recruitment and the mechanisms that control in vivo monocyte/macrophage differentiation remain unknown. APPROACH AND RESULTS: Here, we characterized the kinetics and function of Ly6CHi [Lin- (CD3-CD19-NK1.1-Ter-119-) Ly6G-CD11b+] and Ly6CLo [Lin- (CD3-CD19-NK1.1-Ter-119-) Ly6G-CD11b+] monocyte/macrophage subsets in normal and diabetic wounds. Using flow-sorted tdTomato-labeled Ly6CHi monocyte/macrophages, we show Ly6CHi cells transition to a Ly6CLo phenotype in normal wounds, whereas in diabetic wounds, there is a late, second influx of Ly6CHi cells that fail transition to Ly6CLo. The second wave of Ly6CHi cells in diabetic wounds corresponded to a spike in MCP-1 (monocyte chemoattractant protein-1) and selective administration of anti-MCP-1 reversed the second Ly6CHi influx and improved wound healing. To examine the in vivo phenotype of wound monocyte/macrophages, RNA-seq-based transcriptome profiling was performed on flow-sorted Ly6CHi [Lin-Ly6G-CD11b+] and Ly6CLo [Lin-Ly6G-CD11b+] cells from normal and diabetic wounds. Gene transcriptome profiling of diabetic wound Ly6CHi cells demonstrated differences in proinflammatory and profibrotic genes compared with controls. CONCLUSIONS: Collectively, these data identify kinetic and functional differences in diabetic wound monocyte/macrophages and demonstrate that selective targeting of CD11b+Ly6CHi monocyte/macrophages is a viable therapeutic strategy for inflammation in diabetic wounds.
OBJECTIVE: Wound monocyte-derived macrophage plasticity controls the initiation and resolution of inflammation that is critical for proper healing, however, in diabetes mellitus, the resolution of inflammation fails to occur. In diabetic wounds, the kinetics of blood monocyte recruitment and the mechanisms that control in vivo monocyte/macrophage differentiation remain unknown. APPROACH AND RESULTS: Here, we characterized the kinetics and function of Ly6CHi [Lin- (CD3-CD19-NK1.1-Ter-119-) Ly6G-CD11b+] and Ly6CLo [Lin- (CD3-CD19-NK1.1-Ter-119-) Ly6G-CD11b+] monocyte/macrophage subsets in normal and diabetic wounds. Using flow-sorted tdTomato-labeled Ly6CHi monocyte/macrophages, we show Ly6CHi cells transition to a Ly6CLo phenotype in normal wounds, whereas in diabetic wounds, there is a late, second influx of Ly6CHi cells that fail transition to Ly6CLo. The second wave of Ly6CHi cells in diabetic wounds corresponded to a spike in MCP-1 (monocyte chemoattractant protein-1) and selective administration of anti-MCP-1 reversed the second Ly6CHi influx and improved wound healing. To examine the in vivo phenotype of wound monocyte/macrophages, RNA-seq-based transcriptome profiling was performed on flow-sorted Ly6CHi [Lin-Ly6G-CD11b+] and Ly6CLo [Lin-Ly6G-CD11b+] cells from normal and diabetic wounds. Gene transcriptome profiling of diabetic wound Ly6CHi cells demonstrated differences in proinflammatory and profibrotic genes compared with controls. CONCLUSIONS: Collectively, these data identify kinetic and functional differences in diabetic wound monocyte/macrophages and demonstrate that selective targeting of CD11b+Ly6CHi monocyte/macrophages is a viable therapeutic strategy for inflammation in diabetic wounds.
Authors: Simon Yona; Ki-Wook Kim; Yochai Wolf; Alexander Mildner; Diana Varol; Michal Breker; Dalit Strauss-Ayali; Sergey Viukov; Martin Guilliams; Alexander Misharin; David A Hume; Harris Perlman; Bernard Malissen; Elazar Zelzer; Steffen Jung Journal: Immunity Date: 2012-12-27 Impact factor: 31.745
Authors: G E Reiber; L Vileikyte; E J Boyko; M del Aguila; D G Smith; L A Lavery; A J Boulton Journal: Diabetes Care Date: 1999-01 Impact factor: 19.112
Authors: Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley Journal: Science Date: 2010-02-05 Impact factor: 47.728
Authors: Anna M Boniakowski; Aaron D denDekker; Frank M Davis; Amrita Joshi; Andrew S Kimball; Matthew Schaller; Ron Allen; Jennifer Bermick; Dylan Nycz; Mary E Skinner; Scott Robinson; Andrea T Obi; Bethany B Moore; Johann E Gudjonsson; David Lombard; Steve L Kunkel; Katherine A Gallagher Journal: J Invest Dermatol Date: 2019-06-15 Impact factor: 8.551
Authors: Frank M Davis; Matthew A Schaller; Aaron Dendekker; Amrita D Joshi; Andrew S Kimball; Holly Evanoff; Carol Wilke; Andrea T Obi; William J Melvin; Karen Cavassani; Melissa Scola; Beau Carson; Stephanie Moser; Victoria Blanc; Milo Engoren; Bethany B Moore; Steven L Kunkel; Katherine A Gallagher Journal: Arterioscler Thromb Vasc Biol Date: 2019-09-05 Impact factor: 8.311
Authors: Nina Kosaric; Waracharee Srifa; Clark A Bonham; Harriet Kiwanuka; Kellen Chen; Britta A Kuehlmann; Zeshaan N Maan; Chikage Noishiki; Matthew H Porteus; Michael T Longaker; Geoffrey C Gurtner Journal: Mol Ther Date: 2020-05-30 Impact factor: 11.454
Authors: Andrew S Kimball; Frank M Davis; Aaron denDekker; Amrita D Joshi; Matthew A Schaller; Jennifer Bermick; Xianying Xing; Charles F Burant; Andrea T Obi; Dylan Nysz; Scott Robinson; Ron Allen; Nicholas W Lukacs; Peter K Henke; Johann E Gudjonsson; Bethany B Moore; Steve L Kunkel; Katherine A Gallagher Journal: Immunity Date: 2019-07-23 Impact factor: 31.745
Authors: Anna E Boniakowski; Andrew S Kimball; Amrita Joshi; Matt Schaller; Frank M Davis; Aaron denDekker; Andrea T Obi; Bethany B Moore; Steve L Kunkel; Katherine A Gallagher Journal: Eur J Immunol Date: 2018-06-26 Impact factor: 5.532
Authors: Aaron D denDekker; Frank M Davis; Amrita D Joshi; Sonya J Wolf; Ronald Allen; Jay Lipinski; Brenda Nguyen; Joseph Kirma; Dylan Nycz; Jennifer Bermick; Bethany B Moore; Johann E Gudjonsson; Steven L Kunkel; Katherine A Gallagher Journal: JCI Insight Date: 2020-03-12